16 Aug 3 Top Stocks Recommendations by Market Expert
Top Picks for the Current Market
According to Aditya Arora of Adlytick, the Nifty index is currently approaching a crucial support range.
The zone between 19,000 and 19,300 holds significant importance as a support level for the market. The ongoing correction is primarily attributed to substantial selling by Foreign Institutional Investors (FIIs) and institutions over the past ten days.
Additionally, the release of important Federal Open Market Committee (FOMC) minutes on Wednesday night adds to the market’s volatility.
Arora emphasizes that the range of 19,000 to 19,300 is a pivotal zone where he sees an opportunity for buying.
Regarding the stocks that he is currently considering, Arora’s focus is primarily on defensive stocks and those associated with consumer-facing industries. This strategic choice reflects his approach to navigating the market during this period of uncertainty and potential fluctuations.
Arora also expresses optimism about the metal sector, which he sees as potentially gaining momentum at a crucial support level. This suggests that the metal sector might experience favorable movement.
Stock Selection and Strategy:
Arora’s current stock selections lean toward the defensive and consumer-facing stocks.
He provides insights into three specific stocks that he finds attractive:
Also Read: Buy or Sell: Sumeet Bagadia’s 3 Stock Recommendations for This Week
Auro Pharma:
Arora advises purchasing Auro Pharma at Rs 884, with a recommended stop loss at Rs 830. He suggests aiming for a target range of Rs 950 to Rs 1,000.
- Buy at Rs 884
- Stop loss: Rs 830
- Target: Rs 950 to Rs 1,000
Company Information:
Aurobindo Pharma is a leading Indian pharmaceutical company with a global presence.
Headquartered in Hyderabad, India, the company specializes in the development, manufacturing, and marketing of a wide range of generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs).
Business Overview:
Aurobindo Pharma operates across multiple segments of the pharmaceutical industry, including finished dosages, APIs, and over-the-counter (OTC) products.
The company has a strong focus on research and development, enabling it to produce a diverse portfolio of products catering to various therapeutic areas.
Product Overview:
Aurobindo Pharma offers a comprehensive array of pharmaceutical products, including generic medicines, specialty pharmaceuticals, and OTC drugs.
Its product portfolio spans therapeutic areas such as
-Cardiovascular, central nervous system, anti-infective, gastrointestinal, and more.
The company’s commitment to quality and affordability has helped it establish a presence in both domestic and international markets, contributing to its growth and success.
Also Read: Why Analysts are Bullish on This Midcap Stock?
Blue Dart:
Arora also recommends Blue Dart. He proposes a buy at Rs 6,361, advocating a stop loss at Rs 6,070. His target range for Blue Dart is Rs 6,800 to Rs 7,200. Arora highlights that Blue Dart is in the process of recovery from significant support levels following a notable decline.
- Buy at Rs 6,361
- Stop loss: Rs 6,070
- Target: Rs 6,800 to Rs 7,200
Company Information:
Blue Dart Express Limited is a leading logistics and courier company in India.
Headquartered in Mumbai, the company is known for providing reliable and efficient express delivery services, including domestic and international shipments.
Business Overview:
Blue Dart specializes in time-definite and door-to-door delivery services, catering to a wide range of industries such as e-commerce, pharmaceuticals, automotive, electronics, and more.
The company has established a strong network of service points and distribution centers across the country to ensure seamless and swift delivery operations.
Product Overview:
Blue Dart offers a variety of logistics and express delivery solutions, including
-Domestic priority services, international shipping, freight services, and customized solutions for specific industry needs. The company’s commitment to technological innovation and customer satisfaction has contributed to its reputation as a reliable partner for businesses seeking efficient supply chain solutions.
Also Read: “Volatile Markets? These 5 Stocks Offer 40% Upside Potential as Suggested by the Analysts”
CSB Bank:
In the banking and NBFC sector, Arora’s suggestion is to buy CSB Bank at Rs 302, accompanied by a stop loss at Rs 285. He aims for a target range of Rs 330 to Rs 360 for CSB Bank.
- Buy at Rs 302
- Stop loss: Rs 285
- Target: Rs 330 to Rs 360
Company Information:
CSB Bank, formerly known as Catholic Syrian Bank, is a prominent private-sector bank in India.
With its headquarters in Thrissur, Kerala, the bank has a rich history dating back to its establishment in 1920.
Business Overview:
CSB Bank offers a wide range of banking and financial services to its customers, including retail banking, corporate banking, SME banking, and wealth management.
The bank focuses on providing personalized and customer-centric services to meet the diverse financial needs of individuals and businesses.
Product Overview:
CSB Bank provides various banking products and services, including
-Savings and current accounts, fixed deposits, loans, credit cards, insurance, and investment advisory services.
The bank’s emphasis on customer relationships and its commitment to technology-driven solutions have contributed to its growth and expansion in the competitive banking industry.
Please note that we are not SEBI-registered advisors or analysts. All the views shared in this article and all the content shared on aceink.com are only for learning and educational purposes. Any part of the article or any information on Aceink.com should not be interpreted or considered as investment advice. None of the opinions, views, or content posted on Aceink.com constitutes investment advice, as we are not SEBI-registered advisors or analysts.
DISCLAIMER:
We are not SEBI-registered advisors or analysts. All the views shared in this article and all the content shared on aceink.com are only for learning and educational purposes. Any part of the article or any information on Aceink.com should not be interpreted or considered as investment advice. None of the opinions, views, or content posted on Aceink.com constitutes investment advice, as we are not SEBI-registered advisors or analysts.
Aceink.com or any person associated with this website accepts no liability or responsibility for any direct, indirect, implied, or any other consequential damages arising directly or indirectly due to any action taken based on the information provided on this website. Please conduct your own research, and we suggest seeking investment advice only from a SEBI-registered investment advisor.
The views expressed by investment experts, broking houses, news and media houses, rating agencies, etc., are their own and not those of Aceink.com or its management. Aceink.com advises users to consult a SEBI-registered investment advisor before making any decisions.
——————
“Technical Analysis: All You Need to Know for Smarter Investments” Are you ready to unlock the power of…Read More
No Comments